Cipla receives final US FDA approval for ANDA for Difluprednate Ophthalmic Emulsion 0.05%
13 August 2021 -

India-based Cipla Limited (BSE: 500087) (NSE: CIPLA EQ), a global pharmaceutical company, announced on Thursday that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05%.

The product is an AB-rated generic therapeutic equivalent version of Novartis Pharmaceuticals Corporation's Durezol. It will be available for shipping soon.

Difluprednate Ophthalmic Emulsion 0.05% is utilised for the treatment of inflammation and pain associated with ocular surgery and endogenous anterior uveitis.